{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-003136","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2024-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.379419+00:00","generated_at":"2026-06-01T08:28:44.065231+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Anika Therapeutics adds two directors, announces $40M buyback under Caligan deal","bullets":["Appointed Joseph Capper (MIMEDX CEO) and William Jellison (former Stryker CFO) to Board; board expands to 10 then reduces to 9 after 2024 annual meeting.","Authorized $40M share repurchase program: $15M via 10b5-1 by June 2025, remainder open market through June 2026, replacing April 2023 program.","Caligan agrees to standstill, voting commitments, and other provisions under cooperation agreement.","Reaffirmed 2024 adjusted EBITDA guidance of $25-30M, up >75% YoY at midpoint.","New directors join Capital Allocation Committee; no prior relationships or transactions disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-003136","json":"https://secwatch.observer/filing/0001171843-24-003136.json","markdown":"https://secwatch.observer/filing/0001171843-24-003136.md","text":"https://secwatch.observer/filing/0001171843-24-003136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/0001171843-24-003136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/f8k_052824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:28:44.065231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db34e5b31e","claim":"William Jellison was appointed as Director at Anika Therapeutics, Inc..","evidence_excerpt":"the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/0001171843-24-003136-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"eff6fd089c","claim":"Joseph Capper was appointed as Director at Anika Therapeutics, Inc..","evidence_excerpt":"the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/0001171843-24-003136-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}